All In Biotech

Drug Trial Radar · NCT06929806

Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

A Phase III, Randomized, Open-label, Blinded Endpoint, Comparative Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,900

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

Dec 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Pharmacosmos A/SIndustry
Sponsor type
Industry
First posted
Apr 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the IV Iron treatment ferric derisomaltose helps in the treatment of chronic heart failure in people with iron deficiency. The main question it aims to answer is: • How many participants are admitted to the hospital or die from a disease in the heart or blood vessels Researchers will compare treatment with ferric derisomaltose to no treatment with ferric derisomaltose. This will be done to see how well ferric derisomaltose works. Participants will: * Be randomized 50/50 to either treatment with Ferric derisomaltose or to no treatment with ferric derisomaltose * All participants receives standard of care * Visit site 4-5 times and have 7 video/phone-calls

Conditions

  • Chronic Heart Failure
  • Iron Deficiencies

Interventions

  • Ferric DerisomaltoseDrug

    100 mg/mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of cardiovascular deaths and hospitalizations for worsening heart failureTime frame: From enrollment to the end of follow-up at 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Private clinic

    Pasadena, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.